Vaccine Development

We have demonstrated expertise in vaccine development, especially utilizing Psoralen inactivation techniques for bacterial and viral pathogens. This includes culturing bacterial pathogens, inactivation and generation of pilot vaccine stock, animal work, and associated development and utilization of diagnostics for immunogenicity assays.

Furthermore, we have have an extensive publication record applying these psoralen inactivation techniques along with developing the requite assays as shown by some of our selected publications below:

  1. Westcott MM, Blevins M, Wierzba TF, Morse AE, White KR, Sanders LA, et al. The Immunogenicity and Properties of a Whole-Cell ETEC Vaccine Inactivated with Psoralen and UVA Light in Comparison to Formalin. Microorganisms [Internet]. 2023 Aug 9;11(8):2040. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458022/

  2. Sundaram AK, Ewing D, Blevins M, Liang Z, Sink S, Lassan J, et al. Comparison of purified psoralen-inactivated and formalin-inactivated dengue vaccines in mice and nonhuman primates. Vaccine. 2020 Apr 9;38(17):3313–20.

  3. Williams M, Ewing D, Blevins M, Sun P, Sundaram AK, Raviprakash KS, et al. Enhanced immunogenicity and protective efficacy of a tetravalent dengue DNA vaccine using electroporation and intradermal delivery. Vaccine [Internet]. 2019 Jul 26;37(32):4444–53. Available from: https://www.sciencedirect.com/science/article/pii/S0264410X19308710

  4. Maves RC, Oré RMC, Porter KR, Kochel TJ. Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys. Vaccine. 2011 Mar 24;29(15):2691–6.